Imagion Biosystems
Tracked across 1 events · 6 articles · First seen Jun 09, 2026 · Last active Jun 30, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Imagion Biosystems secured AU$3.75 million in new capital, which will fund the commencement of a Phase 2 clinical trial for its MagSense imaging agent in HER2-positive breast cancer. This funding is crucial for advancing its molecular MRI technology.
Jun 25, 2026 · 6 articles
100
Imagion Biosystems secured commitmentsImagion Biosystems Secures AU$3.75M
80
United States — Food and Drug Administration cleared application Imagion BiosystemsImagion Biosystems Secures AU$3.75M
70
CPS Capital Group led capital raise Imagion BiosystemsImagion Biosystems Secures AU$3.75M
ERGEN INTELLIGENCE
Track Imagion Biosystems live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard